# Editorial: Reviews in psychiatry 2022: psychopharmacology

**Authors:** Maris Taube

PMC · DOI: 10.3389/fpsyt.2024.1382027 · Frontiers in Psychiatry · 2024-02-28

## Full-text entities

- **Diseases:** metabolic disturbance (MESH:D024821), depressed (MESH:D003866), weight gain (MESH:D015430), bipolar affective disorder (MESH:C564108), psychotic, affective symptoms (MESH:D000341), psychiatric disorders (MESH:D001523), dementia (MESH:D003704), schizophrenia (MESH:D012559), insomnia (MESH:D007319), Somnolence (MESH:D006970)
- **Chemicals:** haloperidol (MESH:D006220), clozapine (MESH:D003024), Vortioxetine (MESH:D000078784), metformin (MESH:D008687), risperidone (MESH:D018967), chlorpromazine (MESH:D002746), perospirone (MESH:C065533), perphenazine (MESH:D010546), ziprasidone (MESH:C092292), flupentixol (MESH:D005475), Amisulpiride (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10933095/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC10933095/full.md

---
Source: https://tomesphere.com/paper/PMC10933095